HUMAN-FRATERNITY-MEETING
8.5.2020 17:44:11 CEST | Business Wire | Press release
The Higher Committee of Human Fraternity (HCHF), called on religious leaders and faithful around the world to a day of fasting, prayers and supplications for the good of all humanity on Thursday, May 14 for an end to the novel coronavirus (COVID-19) pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200508005369/en/
The call is part of the Committee’s (HCHF) efforts to realize the objectives of the Document on Human Fraternity. It invites people around the world to lay all their differences aside and come together and assume their responsibilities against this virus, the first and true enemy of humanity in this era.
Judge Mohamed Abdel Salam , Secretary-General of the Committee (HCHF) said: “The overwhelming response with this call for prayer from leaders and peoples around the world is a true testament to human solidarity and grants us hope in achieving global unity based on human fraternity principles for the safety, security and health of all mankind.”
He also noted that seeing all believers come together in prayers and supplications for an end to this pandemic is dream come true of a universal human unity, which is much needed now more than ever. “We will implore God Almighty for his grace and mercy and trust that He will respond to the hopes of millions of faithful asking to be saved from this deadly pandemic,” he continued.
US-based Rabbi M. Bruce Lustig, Senior Rabbi at Washington Hebrew Congregation and member of the Committee (HCHF) added: “Just as all of us have seen how the global pandemic has taken lives and livelihoods, we have also witnessed it reveal some of the best qualities in humankind.”
Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis and member of the Committee (HCHF), said: “As we await a cure that would spare humanity from this deadly pandemic, our only hope is that God Almighty will save the millions suffering around the world, and help scientists and researchers to succeed in finding the eagerly-awaited cure.”
The Committee (HCHF) seeks to bring humanity together in prayer on Thursday, May 14, in what will be the largest gathering of humanity for one goal. The event will be accompanied by unprecedented media coverage, through the Committee’s social media accounts with hashtag #PrayForHumanity to allow people to interact and share their videos, photos and posts.
The Committee (HCHF) is an independent body of religious leaders, educational scholars and cultural figures from across the world, dedicated to achieving the noble goals of the Document on Human Fraternity signed by Pope Francis and Sheikh Ahmed el-Tayeb, Grand Imam of Al-Azhar, during the Pope’s Apostolic Journey to the United Arab Emirates in February 2019, under the patronage of H.H Sheikh Mohammed Bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200508005369/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
